skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - Ónæmisbælandi lyf - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
vibeden stungulyf, lausn 1 mg/ml
sandoz a/s* - hydroxocobalaminum hýdróklóríð - stungulyf, lausn - 1 mg/ml
mucolysin freyðitafla 600 mg
sandoz a/s* - acetylcysteinum inn - freyðitafla - 600 mg
paracetamol sandoz filmuhúðuð tafla 500 mg
sandoz a/s* - paracetamolum inn - filmuhúðuð tafla - 500 mg
vagidonna leggangatafla 10 míkróg
sandoz a/s* - estradiol - leggangatafla - 10 míkróg
zofran filmuhúðuð tafla 4 mg
sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg
zofran filmuhúðuð tafla 8 mg
sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg
zofran mixtúra, lausn 0,8 mg/ml
sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml
anatera stungulyf, lausn 10 %
alcon nordic a/s - fluoresceinum natríum - stungulyf, lausn - 10 %
vigamox (moxifloxacin alcon) augndropar, lausn 5 mg/ml
novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml